New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer Research® (AACR) Annual Meeting 2025, being held April 25-30 in Chicago.

"At Castle Biosciences, our commitment to advancing care for melanoma patients helps drive our continuous innovation," said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, of Castle Biosciences. "The new data being presented at AACR underscores this commitment and further advances our mission to improve health through innovative tests that can help guide personalized treatment strategies designed to enhance patient outcomes.”

Castle will present the following posters at AACR (all times Central Time). The corresponding abstracts are available on AACR’s website using the inline links below.

DecisionDx-Melanoma

• Abstract 3344: The 31-gene expression profile identifies patients at risk of developing early distant metastases and can guide risk-appropriate surveillance strategies
• Lead Author and Presenter: Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
• Session Category: Clinical Research
• Session Title: Prognostic Biomarkers 2
• Location: Poster Section 32
• Poster Board Number: 14
• Date & Time: April 28, 2-5 p.m.
• Summary: Building on findings presented at ASCO 2024, this study demonstrates that DecisionDx-Melanoma can identify early-stage CM patients (American Joint Committee on Cancer (AJCC) stage I-II, n=1,661) at higher risk of distant metastasis (DM) not only to the central nervous system (CNS), but also to the lung, liver and bone. Patients with Class 2B (highest risk) results showed significantly higher DM rates compared to Class 1A (lowest risk) patients across all sites: CNS (7.4% vs. 0.9%, p